尼洛替尼治疗伊马替尼治疗6个月时bcr-abl转录本水平未达到≤10%的cml-cp患者的临床观察

《尼洛替尼治疗伊马替尼治疗6个月时bcr-abl转录本水平未达到≤10%的cml-cp患者的临床观察》由会员上传分享，免费在线阅读，更多相关内容在学术论文-天天文库。

1、授予单位代码10089学号或申请号20123030HebeiMedicalUniversity硕士学位论文专业学位尼洛替尼治疗伊马替尼治疗6个月时BCR-ABL转录本水平未达到$10%的CML-CP患者的临床观察研究生：马艳菲导师：罗建民教授专业：内科学二级学院：第二医院2015年3月河北医科大学学位论文使用授权及知识产权归属承诺本学位论文在导师（或指导小组）的指导下，由本人独立完成。本学位论文研究所获得的研究成果，其知识产权归河北医科大学所有。河北医科大学有权对本学位论文进行交流、公开和使用。凡发表与学位论文主要内容相关的论文，第一署名为单位河北医科大学，试验材料、原始数据、申报的专利

2、等知识产权均归河北医科大学所有。否则，承担相应法律责任。研究生签名：系您各导师签章二级学院领f盖章：.>/义年4月？/日河北医科大学研究生学位论文独创性声明本论文是在导师指导下进行的研究工作及取得的研究成果，除了文中特别加以标注和致谢等内容外，文中不包含其他人已经发表或撰写的研究成果，指导教师对此进行了审定。本论文由本人独立撰写，文责自负。目录中文摘要···········································································································1英文摘要········

3、···································································································4英文缩写···········································································································8研究论文尼洛替尼治疗伊马替尼治疗6个月时BCR-ABL转录本水平未达到≤10%的CML-CP患者的临床观察前言······························

4、·············································································9材料与方法·······························································································9结果··········································································································12附图······

5、····································································································15附表··········································································································16讨论···················································································

6、·······················19结论··········································································································25参考文献··································································································25综述慢性粒细胞白血病的治疗选择···········································

7、·················29致谢··················································································································44个人简历·············································································